Pharmacological approaches targeting the cardiac ryanodine receptor (RyR2) are discussed as potential therapeutic strategies for managing ryanopathies, including heart failure and arrhythmias.
This review summarizes the pathological mechanisms of ryanopathies and discusses pharmacological approaches targeting the cardiac ryanodine receptor (RyR2).
Cardiac diseases are the leading causes of death, with a growing number of cases worldwide, posing a challenge for both healthcare and research. Therefore, the most relevant aim of cardiac research is to unravel the molecular pathomechanisms and identify new therapeutic targets. Cardiac ryanodine receptor (RyR2), the Ca2+ release channel of the sarcoplasmic reticulum, is believed to be a good therapeutic target in a group of certain heart diseases, collectively called cardiac ryanopathies. Ryanopathies are associated with the impaired function of the RyR, leading to heart diseases such as congestive heart failure (CHF), catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmogenic right ventricular dysplasia type 2 (ARVD2), and calcium release deficiency syndrome (CRDS). The aim of the current review is to provide a short insight into the pathological mechanisms of ryanopathies and discuss the pharmacological approaches targeting RyR2.
Szentandrássy et al. (Mon,) conducted a review in Ryanodine Receptor-Associated Heart Diseases (Ryanopathies). Pharmacological approaches targeting RyR2 was evaluated. Pharmacological approaches targeting the cardiac ryanodine receptor (RyR2) are discussed as potential therapeutic strategies for managing ryanopathies, including heart failure and arrhythmias.